Todd C. Davis - 30 Jun 2025 Form 4 Insider Report for LIGAND PHARMACEUTICALS INC (LGND)

Role
Chief Executive Officer, Director
Signature
By: /s/ Andrew Reardon, Attorney-in-Fact For: Todd C. Davis
Issuer symbol
LGND
Transactions as of
30 Jun 2025
Net transactions value
+$21,221
Form type
4
Filing time
02 Jul 2025, 19:31:45 UTC
Previous filing
11 Jun 2025
Next filing
03 Jul 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Davis Todd C Chief Executive Officer, Director 555 HERITAGE DRIVE, SUITE 200, JUPITER By: /s/ Andrew Reardon, Attorney-in-Fact For: Todd C. Davis 02 Jul 2025 0001392029

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LGND Common Stock Other $21,221 +233 +0.14% $91.08 161,467 30 Jun 2025 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were acquired under the Ligand Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).